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 Abstract 1 
Background: Recently, using nano-analytical electron microscopy, we showed that human 2 
valve cusps, coronary arteries and aortae, with and without calcific disease, harbour 3 
spherical calcium phosphate micro-particles of the identical composition and crystallinity. 4 
Importantly these calcified particles were present prior to any clinical sign of calcification and 5 
as yet, their role remains unknown. Objective: To examine the direct effects of isolated 6 
calcified particles on human valvular cells. 7 
Methods: Calcified particles were isolated from healthy and diseased aortae using 8 
collagenase and hydrazine and characterized by scanning electron microscopy and energy 9 
dispersive x-ray spectroscopy. The calcified particles were quantitated by turbidity and 10 
applied to a monoculture of valvular endothelial cells (VECs)  and interstitial cells (VICs) by 11 
adding them directly into the media. Cell differentiation, viability and proliferation was 12 
analysed. Results: Particles were heterogeneous differing in size and shape and were 13 
crystallized as calcium phosphate. There was a significant difference in the amount of 14 
calcified particles isolated from diseased donors compared to healthy donors (p<0.05), but 15 
there were no differences between the composition of the particles from healthy and 16 
diseased donors. VECs treated with calcified particles showed a significant decrease in 17 
CD31, VE-cadherin and an increase in von Willebrand Factor (vWF) expression, p<0.05, 18 
when treated with calcified particles for three weeks. There was a significant increase in α-19 
SMA and osteopontin (p<0.05), with increased expression of alizarin red and von Kossa in 20 
VICs when treated with the particles for three weeks. VEC and VIC viability was significantly 21 
decreased by the calcified particles (p<0.05) with a significantly increased number of TUNEL 22 
positive VECs (p<0.05) indicating apoptosis. Proliferative capacity of VECs and VICs after 23 
14 days incubation with calcified particles was unchanged. 24 
Conclusion: Isolated calcified particles from human aortae are not innocent bystanders but 25 
induce a phenotypical and pathological change of VECs and VICs characteristic of activated 26 
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and osteoblast-like cells. Therapy tailored to reduce these calcified particles should be 1 
investigated.  2 
Key words: calcified particles, valve endothelial cells, valve interstitial cells, osteogenesis, 3 
endothelial-to-mesenchymal transformation. 4 
Abbreviations:  5 
VEC: valve endothelial cell 6 
VIC: valve interstitial cell 7 
CAVD: calcific aortic valve disease 8 
SEM: scanning electron microscopy 9 
vWF: vonWillebrand Factor 10 
TGFβ1: transforming growth factor 1 11 
  12 
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Introduction 1 
   Calcification is a widespread phenomenon involved in several cardiovascular diseases 2 
such as calcific aortic valve disease (CAVD) and atherosclerosis 1. CAVD is a slowly 3 
progressive disorder of dysregulated calcium deposition, very common in the elderly. It is 4 
found in 26% of the population over the age of 65 2, 3, 35% between 75 and 84 years of age, 5 
and up to 50% of those over 85 4, 5. CAVD ranges from mild valve thickening without 6 
obstruction of blood flow, known as aortic sclerosis, to severe calcification with impaired 7 
leaflet motion, termed aortic stenosis.     8 
   The pathological pathways involved in the initiation, progression and end-stage of CAVD 9 
remain largely unknown. The mechanisms of valve calcification in heart valves appear to be 10 
similar but not identical to those responsible for atherosclerosis 6. This might be at least, in 11 
part, due to the specific nature and responses of valve interstitial and endothelial cells to 12 
different stimuli. Recent studies suggest that underlying mechanisms of CAVD are initiated 13 
at the endothelium leading to inflammation 7, 8.  Activation of inflammatory pathways is 14 
believed to promote cardiovascular calcification by the trans-differentiation of quiescent VICs 15 
into osteoblast-like VICs, forming calcific lesions which accumulate calcium phosphate 16 
mineral 7, 9, 10. Mineral deposits have been shown in human valves 10, 11 and we recently 17 
demonstrated that calcium phosphate particles, composed of highly crystalline 18 
hydroxyapatite associated with 100% of calcific lesions and between 83%-100% in non-19 
calcified regions are present in patients with CAVD 10, 12.  These particles were also detected 20 
in 80% of non-calcified aortic valve tissue from patients that had calcific lesions in another 21 
part of their cardiovascular system.  An analysis of particle size showed a trend for 22 
increasing particle diameter with increasing disease severity 10. Most surprisingly, these 23 
particles were found on 46% of aortic valves in which the cardiovascular system was 24 
apparently entirely free from calcific lesions. Spherical and semispherical deposits together 25 
with lamellar crystals have also been shown in calcified valves 13. Immunolabelling of aortic 26 
valve tissues showed strong positive labelling for early osteoblastic transcription factors 27 
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RUNX2 and Sp7 expression in cells near the spherical particles but no osteocalcin. 1 
Additionally RUNX2 and Sp7 expression was observed in apparently healthy tissue with the 2 
presence of calcified particles. However, detection of these calcified particles does not by 3 
itself prove the hypothesis that these particles contribute to the pathogenesis of CAVD. 4 
Since these particles were present during all stages of CAVD, regardless of the presence of 5 
calcific lesions, it is suggested that these particles are the first mineralized structure formed 6 
and may play a fundamental role in calcific lesion formation and ultimately calcification. 7 
Despite this knowledge, the exact role of these particles in CAVD is still unknown. 8 
   The goal of the present study is to investigate the effects of these calcium phosphate 9 
particles on valvular cells. The calcium phosphate particles were isolated from human donor 10 
aortae and several concentrations of particles were studied in direct contact with a 11 
monoculture of VECs and VICs. Quantification of the particles was assessed by turbidity 14, 12 
scanning electron microscopy was used for characterization of the particles and cellular 13 
behaviour was studied with cell viability, proliferation and differentiation. It is hypothesized 14 
that these particles will stimulate a shift in phenotype of the cells into an activated and 15 
osteogenic phenotype that may progress the calcification process.  16 
 17 
Material and methods 18 
Human healthy aortae and calcified aortae were used for isolation of the particles. We have 19 
ascertained that these particles, whether isolated from valves or aortae, are identical in 20 
nature and healthy and diseased aortae were more readily available. 9 healthy aortae (mean 21 
age 42.1 years; range 4 days-65 years; SD=21.5; 6 females and 3 males) were obtained 22 
from heart valve donors, whose valves were judged unsuitable for clinical use or from 23 
explanted hearts of cardiac transplant recipients. The normal aortae were obtained from 24 
patients free from cardiovascular and valvular complications based on history, macroscopic 25 
and microscopic evaluation. These were unused aortae from healthy, heart donors, most of 26 
whom died from a cerebral haemorrhage due to head trauma with no underlying diseases. 27 
The aortic tissue was taken from adjacent to the aortic valves. Calcified aortic tissues, n=5, 28 
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were from heart donors or explanted hearts at the time of cardiac transplantation whose 1 
aortae showed visible evidence of calcification (mean age 66.3 years; range 54-78 years; 2 
SD=9.3; 2 female and 3 males). For cell isolation, healthy, aortic heart valves, n=7, were 3 
used (mean age 48 years; range 18-59 years; SD=15.0; 2 female and 5 males). These were 4 
also obtained from patients free from cardiovascular and valvular complications based on 5 
history, macroscopic and microscopic evaluation. These were unused valves mostly due to 6 
fenestrations from healthy, heart donors, most of whom died from a cerebral haemorrhage 7 
due to head trauma with no underlying diseases. The valves and aortae were not matched 8 
from donors. All human studies have been approved by the Brompton and Harefield trust 9 
ethics committee and Oxford Hospital. These studies have been performed in accordance 10 
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later 11 
amendments. All donors gave their written informed consent prior to their inclusion in the 12 
study. 13 
 14 
Cell isolation and culture 15 
Healthy human valve leaflets were excised and washed in PBS once. The valve leaflets 16 
were incubated in a collagenase solution (Type A, 0.15% w/v; Roche, Life Sciences, United 17 
States) for 10 minutes at 37 °C under a forceful agitation to remove the VECs. The 18 
undigested tissue was removed, washed with PBS, minced, and incubated further for 3 19 
hours in a fresh collagenase solution at 37 °C under forceful agitation to isolate the VICs. 20 
After centrifuging of the solution with the VECs, the resulting VEC pellets were plated out in 21 
gelatin coated tissue culture flasks. VECs were grown until confluent in endothelial media, 22 
defined as Endothelial Cell Growth Medium 2 (ECGM; PromoCell, Germany) containing 150 23 
U/ml penicillin/streptomycin (P/S; Sigma Aldrich), 2 mM endothelial cell growth supplement, 24 
and 20% heat-inactivated fetal calf serum (FCS; Helena Biosciences, Sunderland, United 25 
Kingdom). The resulting VICs after centrifuging the other solution were grown until confluent 26 
in basic VIC media, defined as basal Dulbecco’s Modified Eagle Medium (DMEM; Sigma 27 
Aldrich) containing 150 U/ml P/S, 2 mM L-Glutamine (L-Glut; Sigma Aldrich), and 10% FCS. 28 
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Once confluent, media is switched for fibroblast media, defined as basal DMEM containing 1 
150 U/ml P/S, 2 mM L-Glut, 2% FCS, 5 µg/ml insulin (Sigma Aldrich), and 10 ng/ml fibroblast 2 
growth factor-2 (FGF2; Peprotech, United Kingdom) and cultured until further analysis. 3 
 4 
Isolation of calcium phosphate particles 5 
Healthy and diseased aortic tissues (1 cm by 1 cm), were excised and incubated overnight in 6 
a collagenase solution (2% w/v; Sigma Aldrich, Saint Louis, MO, United States) at 37 °C. 7 
After which, tissues were homogenized with a tissue grinder and again incubated overnight 8 
in the collagenase solution at 37 °C. After incubation, samples were centrifuged and washed 9 
three times with phosphate buffered saline (PBS; Sigma Aldrich). The resulting pellet was 10 
resuspended in 67% hydrazine solution (Sigma Aldrich) at 55 °C for 2 hours. Samples were 11 
centrifuged, washed once with deionized water and ethanol and stored dried in the freezer. 12 
Isolated particles from donors were not pooled. 13 
 14 
Turbidity 15 
For turbidity of the particles, isolated particles from all donors were suspended in 500 µl 16 
deionized water first. The particles were homogenized and mixed extensively by vortexing 17 
and the use of a pestle. The absorbance of the samples and dilutions were measured by 18 
using the Bio spectrophotometer plus (Eppendorf, New York, United States) at 600 nm, 19 
room temperature. For reproducibility, samples were measured immediately and after 5 days 20 
since the particles tend to sink. 21 
 22 
Scanning electron microscopy/EDS/EDX 23 
 After quantification, samples of different particle donors were viewed for their histology with 24 
scanning electron microscopy. For chemical characterization, energy-dispersive X-ray 25 
spectroscopy (EDS/EDX) spectra were obtained from all samples and specific regions of 26 
interest.  27 
 28 
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Cell Viability, differentiation and proliferation 1 
For cell experiments, these calcified particles were applied to a monoculture of VECs and 2 
VICs by adding them directly into the media and cell viability, proliferation and differentiation 3 
was analyzed. Cell viability was determined by fluorescent labelling with a LIVE/DEAD 4 
Viability kit for mammalian cells (Invitrogen, Life Technologies, United States) whereby 5 
particles from different donors (healthy and diseased; absorbance reading of 1.0 and 0.25, 6 
10, 20, and 50 µl per 500 µl of media) were added to the cells and further cultured for a 7 
week. For apoptosis, cells were fixed after 7 days and stained with the In Situ Cell Death 8 
Detection Kit, Fluorescein 15.  9 
Furthermore, the proliferation assay was carried out with a CellTiter 96 AQueous Non-10 
Radioactive Cell Proliferation Assay kit (Promega, Madison, Wisconsin, United States).  11 
To look at the potential of osteogenesis, differentiation was analysed by immunostainings 12 
and Western blotting. In short, both cell types were seeded, mono-cultured for three weeks 13 
with the particles added to the media (absorbance reading of 1.0, 20 µl per 500 µl of media) 14 
and analyzed for α-SMA, CD31, vWF, Vimentin (Dako), Collagen type I (Biologo), Collagen 15 
type III (Novotec), Osteocalcin (Abgent), SM-22 (Abcam), Osteopontin and CBFA-1 (R&D) 16 
by immunofluorescence and western blotting. Calcium deposits and mineralization was 17 
visualized by immunochemistry. More detailed methods can be found in the Supplemental 18 
Data.  19 
 20 
Statistical analysis 21 
Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, United 22 
States). Prior to analysis of significant differences, data was subjected to a Shapiro-Wilk 23 
normality test. Normal distributed data was subjected to a t-test or one-way ANOVA, 24 
followed by a Tukey post-hoc test. Other data was analyzed by a Kruskall Wallis 25 
nonparametric test. Differences were considered significant for p < 0.05. Data is presented 26 
as mean ± standard deviation. For the Westerns, data is presented as median ± standard 27 
deviation. 28 
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Results 1 
Quantification of calcified particles 2 
   Absorbance values for the two time points from all samples showed good 3 
consistency/reproducibility (Figure 1A, 1B). Particles from the healthy donors (n=9) had a 4 
median absorbance of 1.47 (IQR= 0.33 – 2.14) compared to the significantly higher median 5 
absorbance of the diseased donors (n=5) of 2.96 (IQR= 1.88 – 5.64), p=0.04 (Figure 1C). 6 
The calcified particles from healthy donors showed a maximum absorbance of 2.7 and the 7 
diseased particles showed a minimum absorbance of 1.39. To determine effects of calcified 8 
particles from both the healthy and diseased donors an upper absorbance of 1.0 and a lower 9 
absorbance of 0.25 (by diluting the particles) were subsequently used as a high and low 10 
dose. Higher doses were deemed unsuitable considering the ratio of cells to particles and 11 
resulted in cell toxicity and death. 12 
Scanning electron microscopy showed major diversity within the particles 13 
   A lot of variability in shape was seen in each sample (Figure 2A-B) with spherical and 14 
cubic formed particles. Furthermore, in each sample these different shapes and structures 15 
differed in size. The majority of the calcified particles were spherical in form with equal 16 
variation between the healthy and diseased donors. 17 
Chemical composition of calcified particles  18 
   The majority of the particles, both spherical and cubic, revealed calcium (Ca), phosphorus 19 
(P) and smaller amounts of magnesium (Mg) (Figure 2C,D). However, in a small amount of 20 
particles, a small amount of carbon (C) and sodium (Na) was present (not shown).The 21 
percentage of phosphorus, oxygen, calcium, sodium and magnesium in the particles is 22 
depicted in Figure 2E. There were no differences in the composition of the particles for 23 
healthy and diseased donors. 24 
 25 
 26 
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Calcified particles increase vWF secretion in VECs 1 
   Control, healthy and untreated VECs expressed CD31 (red) and most VECs expressed 2 
weak expression of vWF (green) (Figure 3A). Treatment with calcified particles for 7 days, 3 
whereby particles were added in the media of healthy cells, showed no difference in staining 4 
of vWF and CD31 (not shown). For each treated group no expression of αSMA (red) and 5 
SM22 (green) was found (Figure 3A). No osteoblast markers were observed in VECs before 6 
and after 7 day treatment with the calcified particles (not shown). Only a very small 7 
percentage of the cells from one isolate in the positive control expressed α-SMA (red) and 8 
did not express α-SMA in the control samples. There was no difference between the groups 9 
treated with healthy and diseased aortae donors. 10 
   After 21 days, a higher percentage of cells were positive for CD31 (red) and co-expressed 11 
vWF (green) compared with the samples after one week after treatment with the positive 12 
control (Figure 3B). A higher number of cells demonstrated increased intensity of vWF and 13 
decreased intensity of CD31 staining in both calcified particle treated groups compared to 14 
the control. Expression of α-SMA (red) was seen in the positive control for one isolate while 15 
no cells were positive in the control. In this isolate, no α-SMA expressing endothelial cells 16 
were seen in calcified particle treated groups. No expression of SM22 was seen for each 17 
group or isolate. Weakly positive cells for osteopontin and no osteocalcin were found in 18 
treated groups, including the positive control. 19 
   Immunohistochemical staining showed no nodule formation after 3 weeks but some 20 
increase in alizarin red and ALP staining however osteogenic media (positive control) failed 21 
to induced any significant increase in these markers in VECs. No von Kossa positive staining 22 
was detected in any treated group after 21 days (Figure 4A). There was no difference 23 
between the groups treated with calcified particles from healthy and diseased aortae donors. 24 
 25 
Calcified particles induce a change in phenotype of VICs 26 
   A 7 day treatment was not performed as this time was deemed insufficient for osteogenic 27 
changes. Vimentin was strongly expressed in all VICs in the control group and this 28 
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expression decreased in the positive control and treated groups after 21 days. No α-SMA 1 
was detected in the control group and positive control. In contrast, α-SMA positive cells can 2 
be seen in the healthy and diseased aortae donor groups (Figure 5). Furthermore, intensities 3 
of α-SMA expression varied in these groups indicating different degrees of differentiation of 4 
the VIC phenotype. Control cells expressed no osteopontin, osteocalcin or collagen I with 5 
baseline expression of collagen III. The positive control showed no increase in osteopontin 6 
or osteocalcin but there was a very slight increase in expression of collagen I and III. The 7 
calcified particle treated groups showed very weak expression of osteopontin and 8 
osteocalcin and moderate expression of collagen I and III (Figure 5). 9 
   Alizarin Red and ALP staining of VICs (Figure 4) showed positive staining in over 30% of 10 
VICs and von Kossa staining showed positive staining in over 10% of VICs when treated 11 
with the calcified particles but these stains were negative for the control and positive control. 12 
There was no difference between the groups treated with calcified particles from healthy and 13 
diseased aortae donors. 14 
 15 
Calcified particles induce myofibroblastic and osteoblastic changes 16 
   For the calcified particle treated VECs, there was a significant 1.78-fold decrease in the 17 
expression of VE-CAD p=0.04; a significant 3.05-fold decrease in CD31, p=0.009; a 18 
significant 1.56-fold increase in vWF, p=0.02; no change in α-SMA, p=0.82 and no change in 19 
osteopontin, p=0.35, (Figure 6). The collagen antibodies did not work on Westerns, CBFA-1 20 
and osteocalcin were not detected in VECs before or after treatment. There was no 21 
difference between the healthy and diseased calcified particle treated groups. 22 
   For the VICs treated with calcified particles, there was a significant 2.70-fold increase in 23 
the expression of α-SMA, p=0.03; a significant 3.48-fold increase in the expression of 24 
osteopontin, p=0.01 and there was no change in the expression of CBFA-1, p=0.93, (Figure 25 
6). There was no difference between the groups treated with calcified particles from healthy 26 
and diseased aortae donors. 27 
 28 
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Cell viability is reduced for high concentrations of particles 1 
   Overall, VEC viability remained high after treatment for 7 days (> 80%) using the lower 2 
volumes of 10 and 20 µl of [0.25] and 10 µl of [1.0]. However, for the highest dose of 3 
particles (absorbance reading of 1.0, 20 and 50 µl per 500 µl of media) VECS were 4 
significantly less viable compared to the control (93.83 ± 4.7 % vs 65.38 ± 24.68 %, p < 5 
0.05) (Figure 7A, 7C). There was no difference between the groups treated with calcified 6 
particles from healthy and diseased aortae donors. 7 
   VICs were significantly less viable compared to the control (93.43 ± 9.0 %) when treated 8 
with the lower dose of calcified particles (absorbance reading of 0.25, 10µl per 500µl of 9 
media (84.57 ± 11.5 %) and 20 µl per 500 µl (79.4 ± 16.4 %), p < 0.05). For the highest 10 
doses of calcified particles (absorbance reading of 1.0, 20 µl per 500 µl and 50 µl per 500 µl 11 
of media) VICS were significantly less viable compared to the control (93.43 ± 9.0 % vs 79.9 12 
± 18.3 % and 93.43 ± 9.0 % vs 54.6 ± 22.3 %, p < 0.05) (Figure 7A, 7C). Furthermore, no 13 
differences between healthy and diseased aortae particle treated groups were seen. 14 
   The calcified particle treated groups showed a significantly increased number of TUNEL 15 
positive VECs 15.8% ± 16.0% compared to control = 2.0±3.7%, p=0.005 and VICs, 4.0% ± 16 
4.4% showed no difference in TUNEL positivity compared to control = 3.1% ± 4.3%  (Figure 17 
8A and B). However, it was noted that there were fewer cells present for the treated groups 18 
compared with both controls.  19 
 20 
Proliferative capacity is unchanged by addition of calcified particles 21 
   Proliferative capacity for VECs was not changed for the groups with particles compared 22 
with the control after 7 and 14 days (Figure 8C and 8D respectively). Proliferative capacity 23 
for VICs was unchanged after 7 and 14 days (Figure 8E and 8F respectively) however the 24 
diseased [0.25] group had a higher proliferative capacity compared with the control after 14 25 
days (supplement Figure 1) (p=0.0132). For VECs, there was no difference between the 26 
healthy and diseased donor groups. The positive control was significantly higher compared 27 
to all groups due to the increased concentration of growth factors. 28 
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Discussion 1 
  This study has demonstrated that calcified particles isolated from healthy and diseased 2 
aortic donors have the capacity of inducing phenotypic and pathological remodelling of 3 
human VECs and VICs as well as affecting viability and inducing apoptosis in VECs. 4 
  Turbidity was able to gauge a measure of the particles and this was reproducible and 5 
consistent over different days and has been used with other calcified particles 14, 16. 6 
Therefore, these optical density readings were used as indicator of the concentration and 7 
enabled consistent dosing between samples. A lower range of particle concentration was 8 
used that encompassed the range from the healthy donors at a lower concentration of 9 
particles (absorbance reading of 0.25; [0.25]) and a higher concentration (absorbance 10 
reading of 1.0; [1.0]) representing diseased donors. The particles had a high variability, 11 
differing in shape (spherical and cubic) and size (100 nm to 3.5 µm). No differences in 12 
composition of the particles were found between the healthy and diseased donors however 13 
the amount of calcified particles in the diseased donors was significantly increased and this 14 
has been shown to be greatly increased in diseased valves and aortae 10. The heterogeneity 15 
in the calcified particles has been linked to the physicochemical parameters of their native 16 
growth niche and to the local condition of the extracellular matrix 13. 17 
   Using SEM and energy dispersive x-ray spectroscopy, the isolated calcified particles 18 
demonstrated identical size, shape distribution and spectra to the in vivo detected calcified 19 
particles. Elemental analysis of isolated calcified particles demonstrated peaks for calcium, 20 
phosphorus, oxygen and magnesium as detected for the in vivo particles 10. Though this 21 
elemental composition is similar to that of bone 17, it was shown that surface area electron 22 
diffraction patterns of the in vivo calcified particles were typical of highly crystalline 23 
hydroxyapatite whereas bone consists of a poorly crystalline apatite 10, 17, 18. The origin of 24 
these calcified particles is the subject of ongoing research and they could arise due to a 25 
number of different cellular mechanisms and from a number of different cells. A variety of 26 
bodies are released from cells such as apoptotic bodies, exosomes, matrix vesicles, 27 
extracellular vesicles and microparticles and there is significant overlap in their size and 28 
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structure19, 20. The size range of these calcified particles is considerably larger, ranging from 1 
100 nm up to 2.5 μm in diameter (data from these current samples and from 10), compared to 2 
that of extracellular vesicles released from smooth muscle cells in normal and calcifying 3 
media which was shown to be between 30 and 300nm 21. This lower range also holds true 4 
for exosomes, matrix vesicles and microparticles 22. The larger size of these calcified 5 
particles may arise due to extracellular nucleation of hydroxyapatite through the deposition 6 
of Ca2+ and Pi in the hole zone regions of collagen fibrils within the matrix 
23.   As these 7 
calcified particles represent a novel subparticle population in valves and aortae, further 8 
research is aimed at identifying key cell surface markers and to enable the identification of 9 
the cellular origin. Elevated levels of extracellular calcium has been shown to induce 10 
mineralization of vascular smooth muscle cell-derived matrix vesicles 24 and both smooth 11 
muscle cells 25 and matrix vesicles 26 have been demonstrated in calcified valves. 12 
  Particles from both healthy and diseased donors significantly increased the expression of 13 
vWF in VECs and significantly decreased CD31 and VE-cadherin after 21 days incubation. 14 
In general, vWF plays a key role in haemostasis by recruiting platelets to sites of vascular 15 
damage 27. A higher expression of vWF might be an early sign of endothelial activation 28 16 
and is related to endothelial damage 27, 29.  Calcium phosphate particles were shown to 17 
stimulate IL-8 expression and NF-κB activity in human gingival epithelial cells, which are 18 
both involved in the process of inflammation 30. Endothelial damage and dysfunction is 19 
thought to be the initiating factor modulated by circulating inflammatory cells, proteins and 20 
cyclic strain in the process of calcification and further studies will aim to identify early 21 
indicators of inflammation such as NFκB, adhesion molecules and cytokines after treatment 22 
with calcified particles. VECs treated with calcified particles showed no evidence of 23 
endothelial to mesenchymal (EMT) or osteogenic transformation over 21 days as evidenced 24 
from the data in this study. This suggests that these human VEC isolates, compared to VICs, 25 
are more resistant to a change in their phenotype when exposed to these calcified particles. 26 
One VEC isolate was able to undergo EMT when treated with TGFβ1 and TGFβ1 is a key 27 
initiator for EMT 31. There was no detectable osteocalcin or CBFA-1, no increase in 28 
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osteopontin and no nodules, ALP positive cells or calcium deposits were found when VECs 1 
were treated with calcified particles. Additionally human VEC isolates did not undergo 2 
osteogenic differentiation when treated with osteogenic medium which contrasts to clonal 3 
populations of ovine VECs 32 which were shown to undergo osteogenic differentiation using 4 
standard osteogenic protocols. This difference may be related to species, age, gender 33 and 5 
definitely to isolate type.  6 
   The treatment of VICs for 21 days with the particles showed an increase in myofibroblastic 7 
and osteoblastic differentiation by immuno- and histochemical staining. β-tricalcium 8 
phosphate crystallized micron particles, which resemble the calcified particles used in this 9 
study, have been shown to enhance calcification of human mesenchymal stem cells in vitro 10 
and decrease cell viability 34.  Porcine VICs have been compared with osteoblastic cell types 11 
at different stages of differentiation and it has been suggested that VICs may not need to 12 
progress through an activated myofibroblastic stage before reaching an osteoblast-like 13 
phenotype 35. However, it has been shown that there is a relationship between 14 
myofibroblastic porcine VIC activity and initial calcific nodule formation 36 and that 15 
differentiation of VICs to myofibroblasts was a key mechanistic step in the process of early 16 
mineralization 37. Nodules were not detected at any stage of our experiments, with or without 17 
calcified particles or osteogenic media. Crucially, it must be noted that in the present study 18 
VICs from humans that are fibroblastic in nature 38 and of an older age were used and this 19 
may have slowed their rate of differentiation while other studies used animal VICs of a 20 
younger age which normally are activated in vitro and may have a higher differentiation 21 
potential. Further research of the calcified particles with VICs will include short term analysis 22 
for phenotypic changes to see whether VICs progress through an activated phenotype 23 
before differentiation into an osteoblast-like VIC and to assess early markers of activation 24 
and cell signalling. 25 
   Differentiation of VECs and VICs was assessed separately in this study however there is 26 
cross-talk between these two cell types and they are able to modulate each other’s 27 
16 
 
behaviour. VICs were shown to inhibit osteogenic differentiation and endothelial to 1 
mesenchymal transformation of VECs 39, 40. Additionally VECs were able to reverse VIC 2 
activation 40. A co-culture model would elucidate this cross-talk and enable a better 3 
understanding of the time course, the differentiation capacity of the calcified particles and the 4 
differentiation potential of the cells. The calcified particles were in direct contact with most of 5 
the cells and whether they are able to modulate valvular cells without being in direct contact, 6 
using transwells, warrants investigation. Also there may be synergistic effects with 7 
mechanical loading which could affect valvular behaviour hence co-culture under 8 
physiological haemodynamic loading should be performed. SEM was used to assess contact 9 
between the cells and the calcified particles and showed some embedding of the particles 10 
within the cell membranes, possibly due to their size and sedimentation (Supplemental 11 
Figure 2). However, this was complicated by other cellular membrane-bound structures and 12 
debris and engulfment of the calcified particles by the valvular cells cannot be confirmed as 13 
yet. Further studies using TEM are ongoing and labelling of these particles would give more 14 
insight into their mechanisms and roles in the pathogenesis of calcification. 15 
   VEC viability was significantly decreased by 65% for the highest dose of healthy particles. 16 
Those from diseased donors also showed a decrease but this did not reach significance, 17 
probably due to the limited time period of the experiment. In the treated groups only a few 18 
apoptotic cells can be seen while 50% of dead cells were seen in the cell viability staining. 19 
This may suggest that both donors mainly cause necrosis instead of apoptosis at high 20 
doses. However, a lower percentage of cells were present in the treated groups compared 21 
with the control implying that dead cells were washed away or already had undergone 22 
apoptosis. Therefore, a time course with different concentrations of each donor needs to be 23 
performed in order to distinguish better between apoptosis and necrosis. No differences in 24 
proliferative capacity were seen for VECs with these concentrations for both donor groups.  25 
   VICs treated with a high concentration of healthy donor particles demonstrated significant 26 
cell death. The highest concentration for the diseased donor group, although lower than 27 
17 
 
control, showed no significant difference compared with the control and this may be due to 1 
the short time period. The TUNEL staining showed a similar pattern for VECs. Apoptosis has 2 
been documented in human calcified valves 41, 42 and was shown to be mediated through the 3 
pro-apoptotic cytokines TRAIL 41 and TGFβ1 42. Apoptosis has been thought to lead to 4 
growth of calcium phosphate crystal structures exacerbating the calcification process 43.  5 
Although the proliferative capacity for VICs was not affected by the particles after 7 days, a 6 
significant increase for the low dose of particles from the diseased donor (absorbance 7 
reading of 0.25, 10 µl per 500 µl) was seen after 14 days. This could mean that these VICs 8 
become more activated and thus proliferate more. However, proliferation was not seen for 9 
the high concentration (absorbance reading of 1.0), suggesting this might be causing cell 10 
death.  11 
   Differences between the effect of the calcified particles on cell viability and proliferation for 12 
VECs and VICs may be due to the differences in size or native of the two cell types. VECs 13 
are much smaller than VICs, meaning that a smaller surface area is available to interact with 14 
the particles compared with the larger VICs. This could have led to a higher VEC viability 15 
and could explain the lack of changes in proliferation and osteogenic differentiation. 16 
Differences in physicochemical characteristics of the particles may have a different effect on 17 
valvular cells leading to a different contribution to calcification. Furthermore, apatite is not 18 
toxic to human cells in bones and teeth and used in several in vivo applications 44. However, 19 
it may cause opposite effects in other tissues. Labelling of the different particle structures 20 
and investigating their effects would be very important and could give insights into the 21 
location and mechanisms of interaction with the cells since it was not possible to visualize 22 
them with SEM and check for ingestion (data not shown).  23 
   In conclusion, this study demonstrates that calcified particles isolated from human aortae, 24 
used at these doses, have pathological significance in that they are able to activate a high 25 
percentage of human VECs within 21 days. Calcified particles were able to activate a subset 26 
of VICs to the myofibroblastic and osteoblastic phenotype. The particles also have a 27 
18 
 
significant effect on the viability of both VECs and VICs signifying their clinical importance. 1 
Further work is warranted investigating the signalling mechanisms involved. 2 
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Figures 1 
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 5 
Figure 1. Turbidity measurements of a healthy donor (A), a diseased donor (B) at t1, directly 6 
after preparation and t2, after 5 days for several dilutions of each donor sample and graph 7 
showing median O.D.s and IQR for both groups (C). *p<0.05 8 
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Figure 2. Representative SEM micrographs of the spherical particles isolated from a healthy 16 
(A) and a diseased donor (B). Higher magnification SEM micrograph of the spherical 17 
particles (C) with elemental analysis of different spherical particles in size and structure can 18 
be seen (1=big spherical particle, 2=small spherical particle, 3=big cubic particle and 19 
4=small cubic particle). The representative corresponding EDS spectra were collected at the 20 
numbered sites indicated with a cross on micrographs. Mean percentage of phosphorus (P), 21 
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 C 
23 
 
oxygen (O), calcium 37, sodium (Na) and magnesium (Mg) of the different particles for 1 
healthy (red) and diseased donors (blue) (D). Scale bars indicate 5 µm in A and B; 1µm in C. 2 
  3 
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 1 
Figure 3. Immunostaining of VECs after 7 days of culturing (A). Data labelled as control are 2 
untreated VECs and the positive control is from VECs cultured with TGF-β1. VECs are 3 
25 
 
double stained for CD31 (red) and vWF (green) and double stained for α-SMA (red) and 1 
SM22 (green). Immunostaining of cultured VECs with calcified particles, labelled as calc 2 
part, after 21 days (B). Data labelled as positive control is from VECs cultured with 3 
osteogenic media. VECs are double stained for CD31 (red) and vWF (green), α-SMA (red) 4 
and SM22 (green), and for osteopontin (red) and osteocalcin (red). Scalebars represent 50 5 
µm. 6 
  7 
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 1 
Figure 4. Immunochemical staining of VECs (A) and VICs (B) after 21 days of culturing with 2 
two different donors of particles (calc part) stained for Alizarin Red, ALP and with von Kossa. 3 
27 
 
Light green and van Gieson were used as counterstaining (green and pink, respectively). 1 
Data labelled as positive control is from cells cultured with osteogenic media and the control 2 
is without treatment of the particles. Scalebars represent 100 µm. 3 
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 1 
Figure 5. Immunostaining of VICs after 21 days of culturing with calcified particles. Data 2 
labelled as control is without treatment and the positive control is from VICs cultured with 3 
29 
 
osteogenic media. Coverslips are stained for vimentin (red), α-SMA (red), osteopontin (red), 1 
osteocalcin (green), collagen type I (green), and collagen type III (green). Scalebars 2 
represent 50 µm, inserts for osteopontin show higher magnification. 3 
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Figure 6. Graphs showing quantitative Western data of VECs (A) and VICs (B) treated with 25 
control (Cont; C) and calcified particles (Calc part; CP1, CP2 and CP3). Graphs show 26 
median and interquartile ranges. * p<0.05 27 
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Figure 7. Cell viability of VECs (A) and VICs (B) with different amounts of particles from 13 
healthy and diseased donors after 7 days. For both cell types, several volumes of the 14 
particles are added; 10, 20, and 50 µl per 500 µl media of the ODs 0.25 and 1.0. Green 15 
represent living cells, red represent dead cells and the control did not receive any treatment. 16 
Quantification of the percentage of living VECs (C) and VICs (D) as determined from the 17 
images with MATLAB for healthy and diseased donors. VECs are considerably smaller in 18 
size than VICs. Scale bars, 100 µm. Data are depicted as mean and SD. * p < 0.05. 19 
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Figure 8. TUNEL staining of VECs (A) and VICs (B) after 7 days of culturing with calcified 11 
particles. Green represents apoptotic cells and in blue the nuclei. Scale bars represent 100 12 
µm. Graph showing the proliferation of VECs (C) and VICs (E) after 7 days of culturing and 13 
of VECs (D) and VICs (F) after 14 days of culturing with different amounts of particles. For 14 
the VECs, in red the positive control (with endothelial media), yellow the control (0.4% FCS 15 
in endothelial media without growth factors and particles); for the VICs, in red the positive 16 
control (with fibroblast media), yellow the control (0.4% FCS in basal media without 17 
treatment of the particles); for both cell types, blue represents OD of 1.0 and green an OD of 18 
0.25 used for the particles. Data are depicted as mean and SD. * p < 0.05. 19 
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Supplemental Figure 1. Graph showing the proliferation of VECs (A) and VICs (C) after 7 5 
days of culturing and of VECs (B) and VICs (D) after 14 days of culturing with different 6 
amounts of particles. For the VECs, in red the positive control (with endothelial media), 7 
yellow the control (0.4% FCS in endothelial media without growth factors and particles); for 8 
the VICs, in red the positive control (with fibroblast media), yellow the control (0.4% FCS in 9 
basal media without treatment of the particles); for both cell types, blue represents a 10 
treatment with particles from healthy donors with an OD of 1.0 and 0.25 and green treatment 11 
with particles from diseased donors with an OD of 1.0 and 0.25 used for the particles. Data 12 
are depicted as mean and SD. * p < 0.05. 13 
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 20 
Supplemental Figure 2. Representative SEM micrographs of VECs (A) and VICs (B) after 21 
treatment with calcified particles for 7 days.  Scale bars indicate 50 µm. 22 
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